FUZZY PREDICTION OF INCIPIENT ALZHEIMER’S DISEASE CASES FROM MILD COGNITIVE IMPAIRED CASES

Naturally, aging impedes all the functional systems of the body. However, the severity and time of manifestation of these changes differ and due to the effect of both epigenetics and heredity factors. Alzheimer's disease (AD) which can be defined as a pathological lost of memory and cognitive abilities as a result of brain degeneration, injury to the brain or actions of protein biomarkers is the concern of this paper. We presents a fuzzy criteria for the identification and prediction (prognosis) of acute cognitive impairment cases from mild impaired cases based on the distance values determined between ions generated by Mass Spectrometer surface enhanced laser desorption/ionization assay procedures. The result obtained augments current clinical techniques by way of introducing additional use of Mass Spectra data. It also solves the problems associated with diagnosing AD through longitudinal follow-up practices and bridges the gap between protein biomarkers discovery and AD diagnosis.

[1]  K. Jellinger Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study , 2009, Acta Neuropathologica.

[2]  S. Gupta,et al.  Toward a definite diagnosis of Alzheimer's disease. , 1992, Comprehensive psychiatry.

[3]  Marina Spivak Analysis of Mass Spectrometry Data for Protein Identification In Complex Biological Mixtures , 2010 .

[4]  Andreas Quandt,et al.  Finding regions of significance in SELDI measurements for identifying protein biomarkers , 2006, Bioinform..

[5]  M. MacCoss,et al.  A fast SEQUEST cross correlation algorithm. , 2008, Journal of proteome research.

[6]  L A Hansen,et al.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias. , 1994, Archives of neurology.

[7]  Harald Hampel,et al.  CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease , 2001, Molecular Neurobiology.

[8]  J. Schneider,et al.  Risk of incident clinical diagnosis of Alzheimer's disease–type dementia attributable to pathology-confirmed vascular disease , 2017, Alzheimer's & Dementia.

[9]  Gautam B. Singh,et al.  Classification by Clustering: Saliva MS-SELDI Data for Alzheimer's Disease Diagnosis , 2017, 2017 International Conference on Sensing, Diagnostics, Prognostics, and Control (SDPC).

[10]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[11]  K. Blennow,et al.  The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2014, Alzheimer's & Dementia.